Local News

FDA Extends Protection For Salix Drug

Posted Updated

RALEIGH, N.C. — Salix Pharmaceuticals'

protection against generic competition for its ulcerative colitis drug for young people ages 5-17 has been extended through Jan. 8, 2007, by the Food and Drug Administration.

Salix had sought the additional marketing exclusivity for Colazal in June.

Copyright 2023 by Capitol Broadcasting Company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.